Concepedia

Author

William L. Elliott

University of Auckland

Also Known As

W Elliott, W L Elliott, W. Elliott, W.L. ELLIOTT, W.L. Elliott, WILLIAM L. ELLIOTT, William Elliott, William L. Elliott, William Leland Elliott

61

Publications

3.1K

Citations

23

H-Index

52

Concepts

All Affiliations

University of AucklandPfizer (United States)Cancer Society of New ZealandMichigan Cancer Research ConsortiumIndiana University – Purdue University Indianapolis
WL

About

William L. Elliott is an author at University of Auckland specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

16

21

1K

2

Biochemistry

11

12

757

3

Natural Sciences

9

9

711

4

Health Sciences

2

2

35

5

Engineering

1

1

20

William L. Elliott

×

33

Publications

3K

Citations

22

H-Index

YearCitations

Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts

David W. Fry, Patricia J. Harvey, Paul R. Keller,

Molecular Cancer Therapeutics

2004

1.2K

Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor:  4-(Phenylamino)quinazoline- and 4-(Phenylamino)pyrido[3,2-<i>d</i>]pyrimidine-6-acrylamides Bearing Additional Solubilizing Functions

Jeff B. Smaill, Gordon W. Rewcastle, Joseph A. Loo,

Journal of Medicinal Chemistry

2000

263

Pyrido[2,3-<i>d</i>]pyrimidin-7-ones as Specific Inhibitors of Cyclin-Dependent Kinase 4

Scott N. VanderWel, Patricia J. Harvey, Dennis J. McNamara,

Journal of Medicinal Chemistry

2005

148

2-Substituted Aminopyrido[2,3-<i>d</i>]pyrimidin-7(8<i>H</i>)-ones. Structure−Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity

S. KLUTCHKO, James M. Hamby, Diane H. Boschelli,

Journal of Medicinal Chemistry

1998

130

Tyrosine Kinase Inhibitors. 14. Structure−Activity Relationships for Methyl- amino-Substituted Derivatives of 4-[(3-Bromophenyl)amino]-6-(methylamino)- pyrido[3,4-<i>d</i>]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors for the EGF Family of Growth Factors

Gordon W. Rewcastle, Donna K. Murray, William L. Elliott,

Journal of Medicinal Chemistry

1998

112

Tyrosine Kinase Inhibitors. 18. 6-Substituted 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-<i>d</i>]pyrimidines as Soluble, Irreversible Inhibitors of the Epidermal Growth Factor Receptor

Jeff B. Smaill, H. D. Hollis Showalter, Hairong Zhou,

Journal of Medicinal Chemistry

2000

89

Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8<i>H</i>-pyrido[2,3-<i>d</i>]pyrimidines:  Identification of Potent, Selective Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors

Diane H. Boschelli, Zhipei Wu, S. KLUTCHKO,

Journal of Medicinal Chemistry

1998

84

Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-<i>d</i>]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors

S. KLUTCHKO, Hairong Zhou, R. Thomas Winters,

Journal of Medicinal Chemistry

2006

79

Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups

Alan J. Kraker, James D. Hoeschele, William L. Elliott,

Journal of Medicinal Chemistry

1992

67

Tyrosine Kinase Inhibitors. 6. Structure−Activity Relationships among <i>N</i>- and 3-Substituted 2,2‘-Diselenobis(1<i>H</i>-indoles) for Inhibition of Protein Tyrosine Kinases and Comparative <i>in Vitro</i> and <i>in Vivo</i> Studies against Selected Sulfur Congeners

H. D. Hollis Showalter, Anthony D. Sercel, Boguslawa Leja,

Journal of Medicinal Chemistry

1997

64

Page 1